Related Experiment Video
Updated: Jun 12, 2026

Using the Threat Probability Task to Assess Anxiety and Fear During Uncertain and Certain Threat
Published on: September 12, 2014
Prowess-shock trial: a protocol overview and perspectives
Eliézer Silva1, Luiz Francisco Poli de Figueiredo, Fernando Colombari
1Intensive Care Unit, Hospital Israelita Albert Einstein, Universidade de São Paulo, São Paulo, Brazil. eliezer@einstein.br
Abstract:
Sepsis remains a challenge for intensive care physicians, as it keeps up with high mortality rate in spite of the high costs associated with its treatment. Several studies indicate that the infusion of Drotrecogin-alpha activated (DrotAA) reduce mortality in patients at high risk of death when administered early and secured the appropriate initial treatment of sepsis as recommended by Surviving Sepsis Campaign. Europe and United States of America differ regarding the criteria of high risk of death in sepsis, two or more organ dysfunctions and Acute Physiology and Chronic Health Evaluation 25 or more, respectively. In addition to varied definitions of high risk of death for inclusion of patients in sepsis studies, the possibility of bleeding related to drug use and intrinsic limitations related to study design led the Company to develop a new randomized, multinational, placebo-controlled, double-blind study to assess the effectiveness of drug in patients with septic shock in adults.
Related Concept Videos
The Stanford Prison Experiment
Clinical Trials: Overview
Blinding
Milgram's Obedience to Authority
Clinical Trials
There are four phases in a clinical trial. A phase one...
Experimental Designs

